rimegepant sold brand name nurtec odt among others medication used acute treatment migraine without aura adults prophylactic preventive treatment episodic migraine taken mouth dissolve works blocking cgrp united states rimegepant approved treating acute migraine february approval extended preventing episodic migraine june produced marketed march rimegepant approved medical use united arab emirates rimegepant indicated treatment acute migraine without aura adults preventative treatment episodic migraine rimegepant small molecule calcitonin generelated peptide cgrp receptor rimegepant developed biohaven pharmaceuticals markets drug united states receiving fda approval february approval based evidence one clinical trial subjects migraine favorable results rimegepants first clinical trials followed ongoing studies gepants way second generation gepants emerged includes rimegepant ubrogepant atogepant drugs revealed low number side effects excellent bioavailability due molecular february committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product vydura intended prophylaxis acute treatment applicant medicinal product biohaven pharmaceutical ireland rimegepant approved medical use european union april analgesicrelated article stub help wikipedia expanding ithttpsenwikipediaorgwikirimegepant